



PRO BNP ELEVATION'S DIAGNOSTIC AND PROGNOSTIC IMPACT OF EITHER CARDIOVASCULAR AND NON-CARDIAC EVENTS

^{1*} **Jayashree R**, Lecturer, Department of Perfusion Technology, Vinayaka Mission Research Foundation - SAHS, Payanoor, Chennai, Tamilnadu, India.

ABSTRACT

As the clinical setting, the very first and stable levels of the N-terminal-prohormone BNP (NT-proBNP) and B-type natriuretic peptide (BNP) are often used for recognizing those who have both sudden and ongoing cardiovascular disease. Additionally, BNP/NT-proBNP levels could assist to discriminate among patients who have or lack heart failure when pertains to risk categorization. With the goal to figure out why BNP/NT-proBNP's value as long-term prognosticators vary in cohorts with and without heart failure, we undertook a review of the literature.

INTRODUCTION

Natriuretic peptide receptor-A (NPR-A), natriuretic peptide receptor-B (NPR-B), and natriuretic peptide receptor-C (NPR-C) represent each of the three receptors active in the natriuretic peptide system. Within 16 kilobases, the human NPR-A gene has 22 exons and 21 introns. It appears on chromosome 1q21–22. The animal's counterpart of the NPR-B gene, *Npr2*, is situated on chromosome 4, whereas the human version is discovered on chromosome 9p12–21. The human NPR-C gene extends more than 65 kilobases and makes up of 8 exons and 7 introns. It can be identified on chromosome 5p13–14. Cyclic guanosine monophosphate, additionally referred to as cGMP, is a typical intracellular second messenger which is released by the natriuretic peptide receptors NPR-A and NPR-B. Cyclic nucleotide-gated ion channels, cGMP-dependent protein kinases, and cGMP-binding phosphodiesterase are just some of the proteins that cGMP binds to. NPR-C governs the NP concentrations by biological activity.

A blood test can be identified as a B-type natriuretic peptide (BNP) test. It assesses the concentrations of an individual hormone called a B-type natriuretic peptide in your blood. This test reveals cardiac-related data for your healthcare physician. Blood BNP levels significantly higher than regular might suggest an issue may be amiss with your heart. It may indicate that your body doesn't get enough blood through your heart. Although BNP disappears with the kidneys, impaired kidney activity can potentially be the cause. An identical test known as "amino terminal pro B-type natriuretic peptide" (or NT-proBNP) may be obtained from specific laboratories. The outcomes of the BNP and NT-proBNP tests are analogous, nevertheless NT-proBNP possesses absolute concentrations that are from five to tenfold deeper in comparison to those of BNP Providers utilize


When is a B-type natriuretic peptide (BNP) test performed?

In order for tracking for cardiovascular disease, your physician orders this test to look for an elevated quantity of BNP in your blood. If you suffer from cardiovascular disease symptoms, you could have been assessed for BNP or NT-proBNP.

Symptoms might include the following:

- ✓ A dry or "hacking" cough that gets worse as soon as you lie down.
- ✓ Trouble breathing, dyspnea, or wheezing.
- ✓ Delirium (being made of puzzled).
- ✓ Feeling dizzy or syncope
- ✓ Apathy or a languid feeling.
- ✓ Loss of appetite or vomiting and nausea.
- ✓ Edema, or swelling, in your legs, ankles, feet, and abdomen.
- ✓ Urging less often at night than routine

N-terminal pro b-type natriuretic peptide, or N-BNP, is a protein that is an integral part of the naturally occurring hormone brain natriuretic peptide. Pro-BNP is an instance of "raw material," or precursor molecule, from which




- In scenarios when the heart muscle cells are stretched out such as heart failure, hypertension, or other heart-related illnesses, the cardiac ventricles produce and expel pro-BNP.
- Corin is an enzyme that is primarily located in the heart. It cleaves the precursor molecule pro-BNP into the active hormones BNP and NT-proBNP. Pro-BNP departs the ventricles and is synthesized therein until exiting the bloodstream and propagating throughout the body.
- Further blood levels of pro-BNP constitute a valuable diagnostic marker for several kinds of cardiovascular diseases, particularly heart failure, which are indicative of raised cardiac strain. Pro-BNP, formerly referred to as pro-brain natriuretic peptide, is an amino acid sequence comprised of 108
- Cleavage Into Active and Inactive Forms: Pro-BNP fragments into two distinct parts inside the cells of the cardiac muscle by an enzyme known as Furin.
- The 32 amino acid active hormone identified as BNP (brain natriuretic peptide) contributes in cardiovascular systems in dropping blood pressure while encouraging the kidneys' excretion of sodium and water.
- NT-proBNP (N-Terminal pro B-type Natriuretic Peptide): This 76-amino acid inactive fragment is a biomarker evaluating cardiovascular health and stress detection.
- Receptor Binding: The sequence that collaborates to cell receptors is situated in the C-terminal component of pro-BNP, which transitions becomes active BNP. The physiological effects of BNP, especially diuresis, natriuresis, and vasodilation, are stimulated by this binding.

B-type natriuretic peptide (BNP):

- ❖ Normal: 100 pg/mL or less
- ❖ Increased: Above 400 pg/ml

Concerning N-terminal pro b-type natriuretic peptide, or NT-proBNP

- ❖ For individuals under 75, less than 125 pg/mL is deemed normal.
- ❖ Typically for individuals over 75 years of age: 450 pg/mL or less



Pro-BNP levels may spike in accordance with several kinds of events, which include:

1. Heart Dysfunction
2. Cardiac Irretrieval
3. ventricular fibrillation
4. Elevated blood pressure
5. Heart Valve Disorder
6. Failure of the Renal
7. Immediate Cardiovascular Mortality
8. Heart Hypertension
9. COPD, or chronic obstructive pulmonary disease
10. Severe Infections and Sepsis
11. Gender and Age (greater in women and older persons)
12. A circumstance of obesity

Tabulated comparison to illustrate the differences:

Factor	Cardiac Causes	Non-Cardiac Causes
Common Conditions	Heart failure, valvular disease, coronary artery disease	Renal insufficiency, pulmonary hypertension, critical illnesses
Symptoms	Dyspnea, edema, fatigue	Symptoms related to the underlying non-cardiac condition
Clinical Findings	Abnormal heart sounds, jugular venous distension	Findings specific to other systems (e.g., respiratory distress in pulmonary conditions)
Diagnostic Tests	Echocardiogram abnormalities, elevated cardiac enzymes	Abnormal renal function tests, imaging confirming non-cardiac diagnosis
Response to Treatment	Improvement with heart failure treatment	Improvement with treatment of the underlying condition
Prognosis	Dependent on heart function and response to treatment	Dependent on the underlying condition and its management

Imaging Technique	Cardiac Causes	Non-Cardiac Causes
CT Scan	Cardiac CT for detailed heart structure	Detects lung issues, like pulmonary embolism
MRI	Cardiac MRI for heart damage assessment	Identifies muscle, liver, or other soft tissue diseases
Ultrasound	Echocardiogram for heart function	Evaluates organs like kidneys and liver
Nuclear Imaging	Stress tests and SPECT for blood flow	PET scans for oncology and infection imaging
X-ray	May show enlarged heart or fluid	Quick view of lungs and chest structure
Angiogram/Catheterization	Visualizes heart arteries for blockages	Not typically used for non-cardiac causes

Imaging Technique	Cardiac Causes	Non-Cardiac Causes
MUGA Scan	Assesses ventricular function	Not typically used for non-cardiac causes

Treatment for Heart Failure Management:

1. Diet, exercise, and fluid restriction as lifestyle modifications
2. Medication: [ACE/ARB Inhibitors/diuretics, Beta-Blockers, Ivabradine, ARNIs, SGLT2 Inhibitors, Aldosterone Antagonists]
3. Device therapy: Cardiac resynchronization therapy (CRT), implantable cardioverter-defibrillators (ICDs)
4. Cutting Edge Treatments: [Heart transplant, Left Ventricular Assist Devices (LVADs)]

Handling Circular Circumstances:

1. Renal Dysfunction
2. Disorders of the Lungs
3. Disorders of the Thyroid
4. Infections and Sepsis
5. Low red blood cell count

RESULTS

Based on our study, we discovered that a 1.7-fold greater probability of Major Adverse Cardiovascular Events (MACE) was linked to a one standard deviation rise in log-transformed BNP/NT-proBNP levels (hazard ratio [95% confidence interval]: 1.74 [1.58–1.91], $P < 0.0001$). When studies were analyzed without consideration to the existence of coronary artery disease, this association persisted to be significant, with comparable effect sizes and a large overlap in the confidence intervals (1.75 [1.54–2.0], $P < 0.0001$ vs. 1.74 [1.47–2.06], $P < 0.0001$). When quartile stratification was used for the analysis, similar outcomes were also seen.

REFERENCE

1. Novack ML, Zubair M. Natriuretic Peptide B Type Test. 2023 Apr 23. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. PMID: 32310596.
2. Wang Y, Cao X, Yu J, Zhang Y, Li X, Chen X, Zou J, Shen B, Ding X. Association of N-Terminal Pro-brain Natriuretic Peptide With Volume Status and Cardiac Function in Hemodialysis Patients. *Front Cardiovasc Med*. 2021 Feb 22;8:646402. doi: 10.3389/fcvm.2021.646402. PMID: 33693039; PMCID: PMC7937607.
3. YR, Ye LF, Cen XJ, Lin JY, Fu JW, Wang LH. Low NT-proBNP levels: An early sign for the diagnosis of ischemic heart failure. *Int J Cardiol*. 2017 Feb 1;228:666-671. doi: 10.1016/j.ijcard.2016.11.139. Epub 2016 Nov 9. PMID: 27883979.
4. Hendricks, S., Dykun, I., Balcer, B., Totzeck, M., Rassaf, T., & Mahabadi, A. A. (2022). Higher BNP/NT-proBNP levels stratify prognosis equally well in patients with and without heart failure: a meta-analysis. [European Journal of Heart Failure](#).
5. Kim MS, Lee JH, Kim EJ, et al. Korean guidelines for diagnosis and management of chronic heart failure. *Korean Circ J* 2017;47:555-643. PUBMED | CROSSREF
6. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J* 2021;42:3599-726. PUBMED | CROSSREF
7. Tuttle KR, Alicic RZ, Duru OK, et al. Clinical Characteristics of and Risk Factors for Chronic Kidney Disease Among Adults and Children: An Analysis of the CURE-CKD Registry. *JAMA Netw Open*. 2019;2(12):e1918169. doi:10.1001/jamanetworkopen.2019.18169
8. Scott Mu, Justin B Echouffo-Tcheugui, Chiadi E Ndumele, Josef Coresh, Stephen Juraschek, Tammy Brady, John William McEvoy, Bige Ozkan, Olive Tang, Robert H Christenson, Elizabeth Selvin, NT-proBNP Reference Intervals in Healthy U.S. Children, Adolescents, and Adults, *The Journal of Applied Laboratory Medicine*, Volume 8, Issue 4, July 2023, Pages 700–712, <https://doi.org/10.1093/jalm/jfad024>

9. Doust J, Lehman R, Glasziou P. The Role of BNP Testing in Heart Failure (<https://www.aafp.org/afp/2006/1201/p1893.html>). American Family Physician. 2006 Dec 1;74(11):1893-8. Accessed 3/3/2022.
10. Novack ML, Zevitz ME. Natriuretic Peptide B Type Test (<https://www.ncbi.nlm.nih.gov/books/NBK556136/>). [Updated 2020 Dec 2]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Accessed 3/3/2022.
11. Hernandez AF, Albert NM, Allen LA, Ahmed R, Averina V, Boehmer JP, Cowie MR, Chien CV, Galvao M, Klein L, Kwan B, Lam CSP, Ruble SB, Stolen CM, Stein K; MANAGE-HF Study. Multiple cardiac sensors for management of heart failure (MANAGE-HF) - Phase I evaluation of the integration and safety of the HeartLogic multisensor algorithm

